Barclays PLC Buys 36,203 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Barclays PLC increased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 58.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 97,988 shares of the company's stock after acquiring an additional 36,203 shares during the quarter. Barclays PLC owned about 0.20% of Axsome Therapeutics worth $8,291,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AXSM. JPMorgan Chase & Co. lifted its stake in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after buying an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in Axsome Therapeutics during the 4th quarter valued at about $2,599,000. Intech Investment Management LLC lifted its holdings in shares of Axsome Therapeutics by 46.5% in the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock worth $1,356,000 after buying an additional 5,087 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $14,771,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after acquiring an additional 5,438 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AXSM shares. Mizuho boosted their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research report on Thursday, March 27th. Royal Bank of Canada lifted their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a research report on Wednesday, February 19th. HC Wainwright reaffirmed a "buy" rating and issued a $200.00 target price on shares of Axsome Therapeutics in a research note on Thursday, April 3rd. Jefferies Financial Group assumed coverage on shares of Axsome Therapeutics in a report on Monday, April 7th. They issued a "buy" rating and a $200.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft started coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Axsome Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $169.80.

Axsome Therapeutics Stock Up 2.7 %

Axsome Therapeutics stock traded up $2.88 during mid-day trading on Tuesday, hitting $110.12. The company had a trading volume of 75,077 shares, compared to its average volume of 680,709. The company has a market capitalization of $5.37 billion, a PE ratio of -18.32 and a beta of 0.88. The stock's 50 day moving average price is $115.15 and its two-hundred day moving average price is $103.38. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. As a group, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 22.40% of the company's stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.